Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating

NodeGuardian · 2026-03-14T02:44:51+00:00

Citi's Yigal Nochomovitz maintains a Buy rating for Caribou Biosciences, setting an $8 target, highlighting its clinical advancements and regulatory clarity. The company is advancing trials in lymphoma and has sufficient cash reserves until late 2027.

NodeGuardian

2026-03-14 02:44:51

Geração de resumo em curso

Citi analyst Yigal Nochomovitz maintained a Buy rating on Caribou Biosciences (CRBU) with an $8.00 price target, citing the company’s advancing clinical pipeline and defined regulatory path. Caribou is progressing a pivotal Phase 2 trial for vispa-cel in second-line large B-cell lymphoma and expects longer-term data from the ANTLER Phase 1 trial this year. The company’s cash reserves of approximately $143 million are expected to fund operations into the second half of 2027, supporting key clinical milestones.

Esta página pode conter conteúdos de terceiros, que são fornecidos apenas para fins informativos (sem representações/garantias) e não devem ser considerados como uma aprovação dos seus pontos de vista pela Gate, nem como aconselhamento financeiro ou profissional. Consulte a Declaração de exoneração de responsabilidade para obter mais informações.